Abstract
INTRODUCTION
Non-prescription medicines (NPMs), also known as over-the-counter (OTC) medicines, are used for the management of minor ailments. They are convenient for consumers and can be obtained from community pharmacies and other retail outlets e.g. petrol stations and supermarkets. NPMs facilitate self-care which brings about benefits for both the individual and the National Health System (NHS) by reducing the burden on other healthcare settings.
1, 2 A recent study estimated that 13% and 5% of general practice and emergency department (ED) consultations, respectively, were for minor ailments suitable for management in community pharmacies. 3 Symptom resolution was shown to be similar for minor ailments irrespective of setting whilst overall costs are significantly lower for pharmacy consultations compared with general practice and ED consultations. 4 In 2007, there were an estimated 57 million GP consultations per year for minor ailments at a total cost of £2 billion to the NHS. 5 Whilst NPMs are often perceived by the public as being safer than prescription medicines, 6 they can cause harm. NPMs have the potential to be misused, abused and lead to dependence. 7 Specific NPMs most frequently associated with dependence are those capable of causing tolerance and withdrawal e.g. codeine-containing analgesics and smoking cessation products containing nicotine. [8] [9] [10] However, the psychological aspects of addiction may occur with any substance, including NPMs. 11 There are other harms associated with NPM including direct physiological or psychological harm, harm from another ingredient and associated social and economic problems. 7 Codeine-containing analgesics are commonly associated with abuse and dependence due to the properties of codeine with studies highlighting the morbidity caused by their additional ingredients, i.e. paracetamol or ibuprofen. 12 In response to these harms, regulation has been applied in the UK to minimise the risk of harm. This includes restricted indications, limits on pack size, and warnings on packets, patient information leaflets and advertisements. 13 Codeine containing products contain an additional specific warning about the risk of addiction.
Despite the drive to encourage and enable self-care in the UK, 1, 2, [14] [15] [16] there is minimal information about the prevalence of NPM misuse, abuse and dependence in the general population. Much of the existing research focuses on pharmacists' perceptions of prevalence. [17] [18] [19] [20] [21] Patient reported behaviour tends to be highly specific in terms of the population or the outcome measured e.g. misuse of NPMs in community dwelling older adults and in people with HIV. 22, 23 Interviews with members of the general public in Northern
Ireland found that almost a third of respondents (n=298) had personally encountered OTC abuse, although this included personal experience, knowledge or observation, and was solely in relation to abuse. 24 The current study was designed to estimate the prevalence of and factors associated with self-reported NPM misuse, abuse and dependence in the general UK population. For the purpose of this study, NPM misuse was defined as the use of an NPM for a legitimate medical purpose, but in an incorrect manner, e.g. in terms of dosage or duration of use. 18, 25, 26 Abuse was defined as use for a non-medical purpose, e.g. to achieve mind-altering effects or weight loss. 18, 25, 26 Dependence and addiction were defined as "the repeated use of a non-prescription medicine in which the person has a need or desire to use the nonprescription medicine and has difficulty in voluntarily stopping or altering their use".
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METHODS
Study design and participants
This was a cross-sectional postal survey of a random sample of 1000 individuals aged 18 years and older drawn from the UK Edited Electoral Register.
Questionnaire Development
Questionnaire development was informed by the literature, including previous surveys, 28, 29 and discussion with researchers with expertise in this area. The terms "misuse" and "abuse"
were not used in the questionnaire to avoid potential stigmatisation and to reduce the likelihood of social desirability and responder bias. Instead, respondents were asked to indicate if they had ever knowingly used NPMs in specific ways e.g. "for a reason that was not recommended by the manufacturer e.g. for the feeling or effect it caused" (i.e. abuse) or "at a higher dose than recommended by the manufacturer" (i.e. misuse). The definition of dependence and addiction (above) was provided at the beginning of the relevant section.
Pre-piloting and piloting
Pre-piloting was conducted with an opportunistic sample of 23 academic staff and students.
All were asked to complete the questionnaire and provide feedback on clarity and ease of completion. The questionnaire was also reviewed by the Project Director of Over-Count Drugs Information Agency (http://over-count.weebly.com/), a voluntary organisation which provides a telephone helpline and online discussion forum for people dependent on NPMs.
Formal piloting tested both the distribution process and phrasing of the questionnaire. A cover letter, questionnaire, feedback form and reply-paid envelope were posted to a random sample of 100 individuals from the Edited Electoral Register. A pre-notification letter and reminder were used. Questionnaires were returned by 42 of the 100 addressees. Completed questionnaires were examined to identify problems. A list was compiled of feedback from participants and problems identified by examining the completed questionnaires; this informed the refinement of the final questionnaire.
Procedures
In August 2013, a pre-notification letter (to enhance response rate 30 ) was sent to a random sample of 1000 individuals aged ≥18 years from the UK Edited Electoral Register (provided by an independent commercial marketing company) to notify them of the survey. Two weeks later, addressees were sent a cover letter, questionnaire and reply paid envelope.
Reminders were sent to non-responders at two and four weeks. Reminder letters included a questionnaire and reply-paid envelope.
Data management and analysis
Data were entered and analysed using SPSS (Version 22). An independent quality assurance check was conducted on data entry by a research secretary for 10% of questionnaires; these were selected using a random sequence generator.
Sample size
An estimated prevalence of 15% for misuse and abuse, and 5% for dependence, was used for the sample size calculation for the current study based on earlier estimates 8, 10, 22, 23, 31 ; however these studies were restrictive in terms of their populations, the NPMs of interest and the type of inappropriate use measured. A respondent group of 300 was required to detect a 5% prevalence of dependence with 2.5% precision (95% Confidence Interval (CI)
2.5% to 7.5%) and a 15% prevalence of misuse with 4% precision (95% CI 11.0% to 19.0%).
A minimum expected response rate of 30% (n=300) implied this needed to be inflated to an overall sample of 1000.
Statistical methods
Chi-squared tests compared respondents' sex and country of residence with those of nonrespondents. A Mann-Whitney U test was used to compare the distribution of year of birth as the data for this variable were not normally distributed. Chi-squared tests compared respondents' age, sex, ethnicity, partnership status and general health with data from the 2011 UK Census to determine the representativeness of respondents compared to the general population.
Chi-squared tests were used to examine univariate associations between categorical characteristics and misuse/abuse status. An independent samples t-test was used for age as the data were roughly normally distributed. Significant associations (p<0.05) were entered into a binary logistic regression model using the enter method to produce unadjusted ORs and 95% CIs to determine which characteristics were independently related to self-reported misuse/abuse of NPMs.
Preliminary basic descriptive analysis was undertaken on the full dataset. Where possible and logical and without distortion of findings, aggregations were made in order to ensure sufficient numbers for analysis and allow comparison with national data.
RESULTS
Participants
The overall response rate was 43.4% (411/946) ( Figure 1 for electronic version).The prenotification letter was sent to 1000 addressees. Fifty-four addressees were excluded from the denominator due to death, change of address or asking to be excluded from the research prior to receiving the questionnaire.
( Figure 1 for electronic version)
Descriptive data
Respondents' age ranged from 19 to 92 years (mean=60, SD=15. Respondents were significantly older than non-respondents by 10 years (Mann-Whitney U = 86244.0, p<0.001).
The majority of respondents who used NPMs indicated that they always read the directions for use when using a NPM that they have never used before (214/343) and follow the directions for use (243/349) ( Table 2 ).
( Table 2 Prevalence of self-reported non-prescription medicine abuse and misuse)
Non-prescription medicine misuse
The lifetime prevalence of any type of self-reported NPM misuse was 19.3% (n=76, 95% CI 15.7 to 23.5%): 11.9% (n=47, 95% CI 9.1 to 15.5%) for using a higher dose than recommended, 10.6% (n=42, 95% CI 8.0 to 14.1%) for using more often than recommended and 10.6% (n=42, 95% CI 7.9 to 14.0%) for using for a longer time than recommended (Table 2) . Analgesics, with and without codeine, were the most frequently misused products (Table 1 for electronic version).
( Table 1 for electronic version -Categories of non-prescription medicines misused/abused and frequency of misuse/abuse)
Non-prescription medicine abuse
The lifetime prevalence of self-reported abuse was 4.1% (n=16, 95% CI 2.5 to 6.5%) ( Table   2 ). The most common reason for abusing a NPM was for sleep or relaxation purposes.
Medicines used for these purposes were: cold and flu products containing sedative antihistamines (n=3), cough remedies (n=2), codeine-containing analgesics (n=2), analgesics without codeine (n=1) and an antihistamine (n=1). A cough remedy was also used by one respondent for another reason: "When trying to conceive, I read that Benylin help make women more likely to conceive as it made secretions more receptive to sperm".
Haemorrhoid products were reportedly used for facial skin-care purposes (n=2), and sore throat products were used for the pleasant taste (n=1) ( Table 1 for electronic version).
Characteristics associated with self-reported misuse/abuse
Respondent characteristics associated (p<0.05) with misuse/abuse were: age; partnership status; level of education; employment status; presence of a long-standing illness, disability or infirmity which requires the regular use of a NPM; and ever having used illegal drugs or legal highs (hereinafter referred to as illicit drug use) ( Characteristics that remained significant independent predictors of misuse/abuse were age, presence of a long-standing illness requiring regular NPM use and illicit drug use status (Table 3 ).
( Table 3 Characteristics associated with non-prescription medicine misuse/abuse and summary of logistic regression model analysis for variables predicting misuse/abuse)
Non-prescription medicine dependence
Most respondents (71.3%, 281/394) were aware of the potential for NPMs to cause dependence or addiction (Table 4 ). In total, 12% (47/396) of respondents indicated that they personally knew at least one person (including family members, friends and colleagues) who had been dependent on or addicted to a NPM. The NPMs associated with dependency or addiction in these people were: analgesics (without codeine (n=14), with codeine (n=13), unspecified (n=7)), smoking cessations products (n=4), laxatives (n=3), sleep aids (n=3), cough remedies (n=2), caffeine tablets (n=2), and decongestants (n=1).
( Table 4 Dependence to non-prescription medicines)
The lifetime prevalence of NPM dependence was 2% (n=8, 95% CI 1.0 to 3.9%); 0.8% (n=3, 95% CI 0.3 to 2.2%) were currently dependent whilst 1.3% (n=5, 95% CI 0.5 to 2.9%) had been dependent in the past. For those who had ever been dependent, analgesics containing codeine (n=4), analgesics without codeine (n=1), a herbal sleep aid (n=1) and nicotine gum (Table 4 ). The individual indicating that they were 'usually' questioned by pharmacy staff was dependent on a codeine-containing analgesic.
Those 'rarely' questioned were dependent on a codeine-containing analgesic (n=1), a smoking cessation product (n=1) and an herbal sleep aid (n=1). The two respondents who were 'never' questioned were dependent on codeine-containing analgesics. No respondents had ever been refused the sale of the NPM of dependence, or had ever been referred to a GP or substance misuse clinic, by a member of pharmacy staff.
The eight respondents who reported ever being dependent on or addicted to a NPM were asked where they had sought help for their dependence or addiction. The three individuals currently dependent selected 'Nowhere -I haven't sought help'. Of the five whose dependence was in the past, two had not sought help, two sought help from a GP, and one from family and friends.
DISCUSSION
Main findings of this study
This is the first study to estimate the prevalence of NPM misuse, abuse and dependence in the UK general population. Lifetime prevalence of any type of misuse was 19.3%. Lifetime prevalence of abuse and dependence was 4.1% and 2%, respectively. The products most commonly misused and abused were codeine containing analgesics, and cough and cold remedies. Dependence was reported with analgesics (with and without codeine), sleep aids and nicotine products. Being younger, having a long-standing illness requiring regular use of NPMs and ever having used illicit drugs were predictive of misuse or abuse of NPMs.
What is already known on this topic
There is a drive to encourage and enable self-care in the UK through the use of NPMs for minor ailments. Pharmacy customers who make direct product requests by name are less likely to be questioned by pharmacy staff than customers/patients seeking advice regarding the management of conditions or symptoms. 33 Furthermore, pharmacy users generally report low rates of information disclosure to pharmacy personnel during consultations for
NPMs. 28 From a pharmacy perspective, pharmacists suspect that NPMs are sometimes misused. 20 Research has also demonstrated that NPMs can be misused, abused or lead to dependence for some people. 7 The prevalence of these problems within the UK general population was unknown. Previous surveys have been conducted but these were limited in either the population studied or type of NPM studied.
What this study adds
This study identified potential predictors of misuse/abuse as: being of younger age, having a long-standing illness which requires regular NPM use, and use of illicit drugs. Having a longstanding illness is clinically relevant as it reinforces the need for clinicians to be aware of concurrent use of NPMs by their patients, particularly those with pain, and to be mindful of the potential for misuse, abuse and dependence.
Most individuals ever dependent on an NPM had not sought formal help for their dependence. The reasons for this are unknown. Previous qualitative research involving individuals with non-prescription codeine dependence found that attempts at self-treatment were often ineffective 9 ; consequently there is a need for future research to identify the barriers and enablers to seeking treatment for NPM dependence. A qualitative study is ongoing by the research team to address this. There may be a need to clarify sources of treatment/support for NPM dependence and raise awareness of these treatment options.
In our study, individuals who were or had been dependent, were generally rarely or never questioned by pharmacy staff about their purchase. More active engagement may be needed by both pharmacy personnel and patients/customers during these consultations, particularly when requests are made for NPMs associated with misuse, abuse and dependence, to explore the need for referral to an appropriate source of support/treatment.
However, previous research indicates that there may be difficulties with this due to the difficulty some pharmacists have in challenging customers or raising their concerns with customers, as well as their lack of confidence about signposting customers to potential sources of support. 34 Respondents' acknowledgement of the potential for NPMs to lead to dependence was high and suggests that there is public awareness that NPMs are associated with risks. However, a considerable proportion of individuals do not always read the directions for use and therefore alternative, or additional, methods of providing important information on medicine risk should be considered, e.g. by pharmacy staff at the time of purchase, through product advertisements or mass media campaigns.
The survey achieved a higher than anticipated response compared with recent studies using the same sampling method. 28, 35 The survey was inclusive with regard to NPMs and was not restricted to a limited selection of NPMs as in previous research. Furthermore it was conducted on a large, national sample, unlike previous research.
Limitations of this study
There may be some response bias given that respondents differed from non-respondents in various ways; they were older and more likely to be: white, married, in a civil partnership or widowed; rate their general health as poorer and reside in Scotland or Wales. 32 A US study indicated that the lifetime prevalence of abuse of non-prescription cough and cold medicines is higher in younger individuals therefore the prevalence of lifetime abuse may be underestimated. 36 The same US study reported that lifetime use of a non-prescription cough or cold medicine "to get high" was 3.0% and 6.6% amongst those aged 12-17 and 18-25 years, respectively, whilst the lowest prevalence rates were among those aged 50-64 years and 65 years and older, respectively. Consequently, the older age of respondents in our study and the exclusion of individuals less than 18 years of age may have underestimated the prevalence of abuse in our study. Similarly, groups that are less likely to have registered to vote or to have opted out of the Edited Electoral Register will be under-represented which may have affected the results in unknown ways. Other factors may also serve to under-or over-estimate the prevalence of misuse, abuse and dependence. Social desirability bias and recall bias may result in under-reporting. The explicit use of the terms "dependence" and "addiction" may have resulted in under-reporting of dependence due to social desirability bias, although the researchers attempted to minimise the likelihood of this for misuse and abuse by avoiding the use of these terms in the questionnaire. The finding that younger age was predictive of lifetime misuse or abuse of NPMs may be due to recency; it may be that older individuals had simply forgotten about previous use. People may have unknowingly misused NPMs. Our study found that 38% of respondents who used NPMs did not always read the directions for use when using a NPM that they have never used before, which was higher than shown previously.
37
Funding
This study was supported by the Society for the Study of Addiction in the form of a PhD studentship awarded to NF.
Acknowledgements
We thank the survey participants. We would also like to thank Lorna Aucott and Megala Thiruvothiyur (Medical Statistics, University of Aberdeen) for statistical support.
Contributors
All authors conceived and designed the work. NF collected, analysed and interpreted the data. All authors drafted the work or revised it critically for important intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. NF and CM are the guarantors. NF had access to all of the study data and can take responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of interest
NF has received financial support for the current work in the form of a PhD studentship from the Society for the Study of Addiction; NF is in receipt of funding in the form of a PhD studentship from the Society for the Study of Addiction and CM is a member of the Society for the Study of Addiction's executive committee.
Ethical approval
Ethical approval was obtained from University of Aberdeen College Ethics Review Board (reference number CERB/2013/3/874).
